INTRODUCTION
Chemotaxis, phagocytosis, and lysosomal enzyme release are recognized functions of the neutrophil in the inflammatory response. Chemotaxis can be defined as the ability of motile cells to recognize and respond to a suitable gradient with directional migration. Presumably, the first step in the molecular mechanism of chemotactic activation includes the binding ofa chemotactic factor to cell receptors. Specific binding of the synthetic chemotactic N-formylmethionyl peptides to rabbit (1) and human (2) polymorphonuclear leukocytes has been described. Although the N-formylmethionyl peptides resemble chemotactic factors produced by bacteria, specific binding to neutrophils by a human cell-derived chemotactic factor has not been demonstrated. The neutrophil-derived crystal-induced chemotactic factor (CCF),1 a glycoprotein with an =8,400 mol wt, is thought to play an important role in the development of acute inflammation induced by monosodium urate and calcium pyrophosphate crystals
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'Abbreviations used in this paper: CCF, crystal-induced chemotactic factor; PBS, phosphate-buffered saline. (3) (4) (5) . The present study demonstrates specific binding of CCF to receptors on the human neutrophil.
METHODS
The CCF was isolated from the lysosomal fraction of human peripheral blood neutrophils allowed to phagocytose monosodium urate crystals. The purification method, previously described (5) , uses differential centrifugation and Sephadex G-50 (Pharmacia Fine Chemicals, Piscataway, N. J.) chromatography followed by preparative polyacrylamide-gel electrophoresis. Human neutrophils and lymphocytes were obtained from healthy donors' blood by a Ficoll-Hypaque (Pharmacia) centrifugation technique followed by dextran sedimentation (6) . The final cell preparations consisted of 95% neutrophils and 92% lymphocytes, respectively, the contaminating cells being mainly erythrocytes. Before binding studies, the cell preparations were exposed to 0.85% ammonium chloride for 5 min to lyse the contaminating erythrocytes, washed, and resuspended in the incubation medium (Hanks' solution, pH 7.4, containing 0.1% bovine serum albumin) (7) at various concentrations. lodinated CCF was obtained using the solid phase lactoperoxidase method (8) (5) , and migrated the same distance (2.5-2.7 cm) from the cathode on polyacrylamidegel electrophoresis as did the unlabeled material (5) .
The binding assay was performed as follows: various concentrations of 1251-CCF and cells were incubated in 0.5 ml of incubation medium for 60 min (unless specified), at 37°C with gentle agitation. Incubation was terminated by adding 0.5 ml ofice-cold incubation medium, followed by centrifugation in a Microfuge (model B, Beckman Instruments Inc., Palo Alto, Calif.) at 8,000 g for 2 min. The supernate was discarded, the pellet resuspended and transferred to another tube, and pelleted again, the supernate removed and the pellet counted for radioactivity in a gamma counter (Isomatic model 707, Baird, Atomic, Inc., Cambridge, Mass.) at 50% efficiency.
The labeled CCF preparation was subjected to binding assays in the presence of excess receptor sites to determine the proportion of radioactivity which represents "active" CCF with the capacity of interact with specific receptor sites. With a single incubation procedure, the maximum neutrophil binding activity of the labeled CCF preparation was found to be 29% of the total radioactivity of the tracer preparation (Fig. 1) . The remaining radioactivity present in the media, after removal of the cells (1 x 107 to 4 x 108), although still precipitable with acetone, showed a linear decrease in chemotactic activity for neutrophils as measured by the 51Cr-radiolabeled technique. At maximum binding there was no chemotactic activity detected in the supernate (Fig. 2) . Likewise, the media of 125I-CCF incubated with 4 The synthetic chemotactic factor glycyl-histidyl-glycine (Gly-His-Gly) (10) was purchased from Sigma Chemical Co. Complement-activated plasma was prepared as previously described (5) . Formyl methionyl-leucyl-phenylalanine (FMet-Leu-Phe) was a generous gift of Dr. Richard J. Freer, Medical College of Virginia, Richmond, Va.
RESULTS
Kinetics of CCF binding. The specific binding of 125I-CCF (0.25 ,uM) to human neutrophils as a function of time at 37°C is shown in Fig. 4 . The binding was rapid with 50% of total binding observed at <10 min, with equilibrium levels observed at 60-90 min. The binding of 1251-CCF to the neutrophils was found to be reversible when nonlabeled CCF (24 ,uM) was added to the mixture (Fig. 4) .
Scatchard analysis of specific 1251-CCF binding revealed the presence of binding sites with a dissociation constant of 0.446 ,M (Fig. 5) . At saturation point, 5.35 pmol of 125I-CCF was bound to the 5 x 106 neutrophils present in the incubation medium. Specific binding was linear with cell concentration over the range of 0-2 x 108 cells.
To investigate the possibility that the observed "binding" might be due to internalization of 125I-CCF, the ability of cells killed by repeated freezing and thawing to bind 1251 radioactivity. The specific binding of 125I-CCF was reduced by 76% at 10 min and by 85% at 60 min after trypsin treatment.
Specificity of binding. The ability of other chemotactic factors to compete with 1251-CCF for binding sites was investigated. Three apparently different chemotactic factors: the synthetic peptides F-Met-Leu-Phe and Gly-His-Gly, and complement-activated plasma were tested for their ability to inhibit CCF binding. Neither F-Met-Leu-Phe (10 uM-10 pM), Gly-His-Gly (37 ,uM-3.7 ,uM), nor complement-activated plasma (10-50 ul) altered the binding of 125I-CCF to human neutrophils in our experimental design (data not shown).
In a separate set of experiments, the binding of 1251. CCF to human erythrocytes (1 x 107-1 X 108) and to human peripheral blood lymphocytes (1 x 107-1 x 108) was investigated. Less than 7% of the binding observed with neutrophils was noticed with either of these cell preparations.
DISCUSSION
Experiments performed in vitro and in vivo strongly suggest a major role for CCF in the development of the acute inflammatory response to monosodium urate crystals and possibly to other crystals as well (3, 4) . The current study presents evidence that the first step in the chemotactic activation of the neutrophil by CCF involves the recognition and binding of CCF to the neutrophils by a specific receptor. Inasmuch as the amount of 1251-CCF bound to intact viable cells and to freeze-thawed cells was essentially identical, and trypsin markedly displaced cell-bound radioactivity, it is likely that the binding observed was not due to endoSpecific Neutrophil Receptor for Chemotactic Factor cytosis. Binding to the cells occurred rapidly, with 50% of the total specific binding observed at <10 min under experimental conditions. Assuming an equimolar ligand-receptor relationship, the number of receptors per cell based on the Scatchard plot was calculated to be -6.44 x 105, a number similar to the one described by Aswanikumar et al. (1) for the synthetic chemotactic factor formyl Norleu-Leu-Phe. Current data suggest that chemotactic factors induce cell response by interacting with a receptor (11) . If we are indeed measuring a specific receptor responsible for mediating chemotaxis in human neutrophils, a close correlation should exist between the Kd of the receptor and the concentration of the chemotactic factor required to give half-maximal chemotactic response (12, 13) . The Scatchard analysis of specific 125I-CCF binding revealed the presence of a binding site with a dissociation constant of 0.446 ,uM a value close to the concentration of CCF required to elicit a half-maximal chemotactic response, 1.5 ,uM (5) . A relationship of a similar degree has been reported by Aswanikumar et al.
(1) for the synthetic factor formyl Norleu-Leu-Phe and its rabbit neutrophil receptor.
Human erythrocytes and peripheral blood lymphocytes showed no significant binding of 125I-CCF. Lymphocytes, although known to respond to a suitable chemotactic challenge (8), do not respond chemotactically to a gradient of CCF (unpublished observation) and human erythrocytes are known to be nonmotile cells. These results suggest a relationship between the presence of specific binding sites on the cell and the ability of a given cell to be chemotactically activated by CCF.
No decrease in binding of 125I-CCF to neutrophils was observed when complement-activated serum or the synthetic chemotactic peptides Gly-His-Gly and F-Met-Leu-Phe were tested in the competition studies. The maximal concentrations of the synthetic chemoattractants tested were well above those required to elicit half-maximal chemotactic response from the human neutrophil (2, 10) . The main active factor in complement activated plasma, C5a (14) , has been described in similar experiments not to compete for binding sites with the formyl peptides (1, 2). These results are in favor of the existence of distinct specific receptors for chemotactic factors in the neutrophil. However, the possibility that receptors may not be required for some chemotactic factor(s) to elicit a chemotactic response in the neutrophil cannot be ruled out.
In conclusion, the cell-derived chemotactic factor CCF binds to human neutrophils in a saturable, timedependent fashion with a calculated dissociation constant of 0.446 ,uM. Binding of the ligand to viable and disrupted cells is alike indicating that binding is not accounted for by endocytosis. The binding is not displaced by the chemotactic substances Gly-His-Gly, F-Met-Leu-Phe, or complement-activated plasma providing evidence for the specificity of the receptor.
